“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP TAZ) Lotion”. 2019. SKIN The Journal of Cutaneous Medicine 3 (November): S31. https://doi.org/10.25251/skin.3.supp.31.